Imvanex Evropská unie - čeština - EMA (European Medicines Agency)

imvanex

bavarian nordic a/s - modifikovaná vakcinie ankara - bavorský nordický virus (mva-bn) - smallpox vaccine; monkeypox virus - jiné virové vakcíny, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 a 5. použití této vakcíny musí být v souladu s oficiálními doporučeními.

Dengvaxia Evropská unie - čeština - EMA (European Medicines Agency)

dengvaxia

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vakcíny - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 a 4. použití dengvaxia by měla být v souladu s oficiálními doporučeními.

Mvabea Evropská unie - čeština - EMA (European Medicines Agency)

mvabea

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemoragická horečka, horečka ebola - vakcíny - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

COVID-19 Vaccine (inactivated, adjuvanted) Valneva Evropská unie - čeština - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vakcíny - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Qdenga Evropská unie - čeština - EMA (European Medicines Agency)

qdenga

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - vakcíny - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Abrysvo Evropská unie - čeština - EMA (European Medicines Agency)

abrysvo

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infekce dýchacích syncyciálních virů - vakcíny - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. viz kapitoly 4. 2 a 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. použití této vakcíny musí být v souladu s oficiálními doporučeními.

Ervebo Evropská unie - čeština - EMA (European Medicines Agency)

ervebo

merck sharp & dohme b.v.  - rekombinantní vezikulární stomatitis virus (kmen indiana) s odstranění obálky glykoprotein, nahrazuje zaire ebolavirus (kmen kikwit 1995) povrchový glykoprotein - hemoragická horečka, horečka ebola - vakcíny - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. použití ervebo by měla být v souladu s oficiálními doporučeními.

VidPrevtyn Beta Evropská unie - čeština - EMA (European Medicines Agency)

vidprevtyn beta

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vakcíny - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 a 5. 1 in product information document). použití této vakcíny musí být v souladu s oficiálními doporučeními.

Zabdeno Evropská unie - čeština - EMA (European Medicines Agency)

zabdeno

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hemoragická horečka, horečka ebola - vakcíny - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.